We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last-reported quarter, the company’s earnings of $1.13 per share surpassed the Zacks Consensus Estimate by 15.3%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, the average beat being 9.2%.
Let’s see how things have shaped up for Abiomed prior to this announcement.
Factors to Note
Per the fiscal 2022 third-quarter earnings call, Abiomed had confirmed that the pandemic had accelerated the rollout of Impella Connect, its remote monitoring technology. Currently, this technology is available in 1,564 hospitals worldwide and around 90% of weekly U.S. patients are monitored in the cloud. This enables round-the-clock patient monitoring despite pandemic-induced hospital restrictions and labor shortages, thereby improving patient management and optimizing care in the ICU. This is likely to have resulted in wider adoption of Impella Connect in the to-be-reported quarter, thereby significantly driving the top line.
Abiomed’s Impella 5.5 with SmartAssist has been performing well over the past few months due to sustained demand. Additionally, in January, the product received approval from Japan’s Pharmaceuticals and Medical Devices Agency and Hong Kong’s Medical Device Division. Given that the Japanese population is averse to heart transplants and invasive sternotomies (as stated by the company), the minimally-invasive Impella 5.5 with SmartAssist is expected to have witnessed an increased adoption. This raises optimism about the stock.
In the last reported quarter, Abiomed registered a solid uptick in its U.S. revenues on the back of strong growth in patient utilization and a favorable sales mix. Strength across the company’s broad base portfolio was also recorded, with robust growth in Impella CP, Impella RP and Impella 5.5 in the last reported quarter. This momentum is expected to have continued in the fiscal fourth quarter as well, given the gradual recovery of hospital-based procedures and patient utilization, thereby driving revenues.
During the fiscal third-quarter earnings call, Abiomed witnessed strength in its Europe (driven by strong performance in Italy, Spain, Belgium and the Middle East, and positive benefit from sales mix) and Japan businesses. The positive benefit from sales mix the company derived from its European business in the last-reported quarter is expected to have continued in the to-be-reported quarter as well as Abiomed fully transitions to Impella CP with SmartAssist and begins to launch Impella 5.5 in Germany. This is expected to have considerably pushed the company’s top line.
During the same call, Abiomed confirmed that clinical feedback for its Breethe OXY-1 System has been favorable. This positive feedback is likely to have continued in the fiscal fourth quarter, leading to robust product adoption and sales.
However, the company has been facing high pricing pressure due to intensifying competition in the key markets for a while now. This is expected to have weighed on the company’s margin expansion in the soon-to-be-reported quarter.
The Estimate Picture
For fourth-quarter fiscal 2022, the Zacks Consensus Estimate of $266.3 million for Abiomed’s total revenues implies an improvement of 10.4% from the prior-year quarter’s reported figure.
The consensus estimate for earnings per share is pegged at $1.09, indicating a decline of 12.1% from the prior-year period’s reported number.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) along with a positive Earnings ESP has higher chances of beating estimates. However, this is not the case here, as you can see:
Earnings ESP: Abiomed has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Stocks Worth a Look
Here are a few medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
Meridian Bioscience, Inc. has an Earnings ESP of +26.32% and a Zacks Rank of 2. Meridian Bioscience has an earnings yield of 5.1% compared with the industry’s 0.4%.
Lucira Health, Inc. has an Earnings ESP of +485.72% and is a Zacks #2 Ranked stock. Lucira Health has an estimated long-term growth rate of 40.2%.
Lucira Health’s earnings surpassed estimates in two of the trailing four quarters, with the average surprise being 8%.
Avanos Medical, Inc. (AVNS - Free Report) has an Earnings ESP of +4.17% and a Zacks Rank of 1. Avanos Medical has an earnings yield of 5.1% against the industry’s negative yield.
Avanos’ earnings surpassed estimates in two of the trailing four quarters, with the average surprise being 6.7%.
Image: Bigstock
Abiomed (ABMD) to Report Q4 Earnings: What's in the Cards?
Abiomed, Inc. is scheduled to report fourth-quarter fiscal 2022 results on Apr 28, before market opens.
In the last-reported quarter, the company’s earnings of $1.13 per share surpassed the Zacks Consensus Estimate by 15.3%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, the average beat being 9.2%.
Let’s see how things have shaped up for Abiomed prior to this announcement.
Factors to Note
Per the fiscal 2022 third-quarter earnings call, Abiomed had confirmed that the pandemic had accelerated the rollout of Impella Connect, its remote monitoring technology. Currently, this technology is available in 1,564 hospitals worldwide and around 90% of weekly U.S. patients are monitored in the cloud. This enables round-the-clock patient monitoring despite pandemic-induced hospital restrictions and labor shortages, thereby improving patient management and optimizing care in the ICU. This is likely to have resulted in wider adoption of Impella Connect in the to-be-reported quarter, thereby significantly driving the top line.
Abiomed’s Impella 5.5 with SmartAssist has been performing well over the past few months due to sustained demand. Additionally, in January, the product received approval from Japan’s Pharmaceuticals and Medical Devices Agency and Hong Kong’s Medical Device Division. Given that the Japanese population is averse to heart transplants and invasive sternotomies (as stated by the company), the minimally-invasive Impella 5.5 with SmartAssist is expected to have witnessed an increased adoption. This raises optimism about the stock.
Abiomed, Inc. Price and EPS Surprise
Abiomed, Inc. price-eps-surprise | Abiomed, Inc. Quote
In the last reported quarter, Abiomed registered a solid uptick in its U.S. revenues on the back of strong growth in patient utilization and a favorable sales mix. Strength across the company’s broad base portfolio was also recorded, with robust growth in Impella CP, Impella RP and Impella 5.5 in the last reported quarter. This momentum is expected to have continued in the fiscal fourth quarter as well, given the gradual recovery of hospital-based procedures and patient utilization, thereby driving revenues.
During the fiscal third-quarter earnings call, Abiomed witnessed strength in its Europe (driven by strong performance in Italy, Spain, Belgium and the Middle East, and positive benefit from sales mix) and Japan businesses. The positive benefit from sales mix the company derived from its European business in the last-reported quarter is expected to have continued in the to-be-reported quarter as well as Abiomed fully transitions to Impella CP with SmartAssist and begins to launch Impella 5.5 in Germany. This is expected to have considerably pushed the company’s top line.
During the same call, Abiomed confirmed that clinical feedback for its Breethe OXY-1 System has been favorable. This positive feedback is likely to have continued in the fiscal fourth quarter, leading to robust product adoption and sales.
However, the company has been facing high pricing pressure due to intensifying competition in the key markets for a while now. This is expected to have weighed on the company’s margin expansion in the soon-to-be-reported quarter.
The Estimate Picture
For fourth-quarter fiscal 2022, the Zacks Consensus Estimate of $266.3 million for Abiomed’s total revenues implies an improvement of 10.4% from the prior-year quarter’s reported figure.
The consensus estimate for earnings per share is pegged at $1.09, indicating a decline of 12.1% from the prior-year period’s reported number.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) along with a positive Earnings ESP has higher chances of beating estimates. However, this is not the case here, as you can see:
Earnings ESP: Abiomed has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Stocks Worth a Look
Here are a few medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
Meridian Bioscience, Inc. has an Earnings ESP of +26.32% and a Zacks Rank of 2. Meridian Bioscience has an earnings yield of 5.1% compared with the industry’s 0.4%.
Meridian Bioscience’s earnings surpassed estimates in three of the trailing four quarters, with the average surprise being 9.3%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Lucira Health, Inc. has an Earnings ESP of +485.72% and is a Zacks #2 Ranked stock. Lucira Health has an estimated long-term growth rate of 40.2%.
Lucira Health’s earnings surpassed estimates in two of the trailing four quarters, with the average surprise being 8%.
Avanos Medical, Inc. (AVNS - Free Report) has an Earnings ESP of +4.17% and a Zacks Rank of 1. Avanos Medical has an earnings yield of 5.1% against the industry’s negative yield.
Avanos’ earnings surpassed estimates in two of the trailing four quarters, with the average surprise being 6.7%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.